Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient (API) supporting its lead oncology candidate, ONC010. The program was conducted in collaboration with Dalton Pharma Services and establishes a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
This milestone strengthens the company's chemistry, manufacturing and controls (CMC) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. Onco-Innovations stated that the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness, while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
The achievement marks a critical step in the development of ONC010, a candidate targeting solid tumors under an exclusive worldwide license to patented technology. By establishing a qualified reference standard, Onco-Innovations ensures that its analytical methods are reliable and reproducible, which is essential for regulatory submissions and eventual clinical trials. Investors can view the full press release at https://ibn.fm/EefIN.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For the latest news and updates, visit the company's newsroom at https://ibn.fm/ONNVF.
